Want to take quizzes and track your credits?
Initial reports about the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic suggested that the incidence of kidney complications was low.1,2 Few would have anticipated the profound effect that the coronavirus disease 2019 (COVID-19) pandemic would have on the field of kidney health care. Early in the pandemic, it became apparent that patients with kidney disease were particularly vulnerable to SARS-CoV-2.3 In addition, it also became apparent that acute kidney injury (AKI) was occurring at several-fold higher rates in hospitalized patients with COVID-19 in the US than in earlier series in China.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Corresponding Author: Wolfgang C. Winkelmayer, MD, MPH, ScD, Section of Nephrology, Baylor College of Medicine, One Baylor Plaza, Ste ABBR R705, MS 395, Houston, TX 77030 (firstname.lastname@example.org).
Conflict of Interest Disclosures: Dr Winkelmayer reported receipt of personal fees from Akebia, AstraZeneca, Bayer, Daichii-Sankyo, Janssen, Merck, Relypsa, and Vifor Fresenius Medical Care Renal Pharma and grants from the National Institutes of Health. Dr Charytan reported receipt of personal fees from PLC Medical, Janssen, GlaxoSmithKline, Merck, and Fresenius; grants and personal fees from Gilead, AstraZeneca, and Amgen; and grants from Bioporto. No other disclosures were reported.
You currently have no searches saved.